Longport's Sale to Britain's Christie Hospital Marks Expansion of EPISCAN I-200 Fight against Skin Cancer.

GLEN MILLS, Pa. -- Longport, Inc. (OTC BB: LPTI), a medical technology specialist in high resolution ultrasound imaging, today announced that it has made a sale of its EPISCAN I-200 to the renown Christie Hospital in Manchester, England.

This marks the first sale of the EPISCAN I-200 for use in conjunction with photodynamic therapy (PDT) for the treatment of basal cell carcinoma, a type of skin cancer, and Bowen's Disease, a very common pre-malignant condition of the skin, and opens an entirely new market for Longport. In addition, the purchase of the EPISCAN I-200 by a leading hospital within the British National Health System is expected to provide a greater profile for Longport in the UK. The purchase is for routine clinical use, and also for clinical research that will result in the further development of PDT. The Christie Hospital PDT group is composed of clinical oncologists with a wide experience in the treatment of pre-malignant and malignant conditions of the skin, and physicists and technicians specializing in the provision of dermal ultrasound imaging.

Paul Wilson, President of Longport, said, "We are every excited by the sale of the EPISCAN I-200 to the Christie Hospital. By applying the scanner's ultrasound imaging technology to measure pre-treatment tumor thickness and to map the regression of basal cell carcinomas as a result of (PDT), we have established a new application for the scanner, effectively opening an entirely new market. Because PDT is a fairly new approach to the treatment of cancer, it is vital that clinicians have accurate and precise imaging to assess how many treatment sessions are likely to be required in order to eradicate the lesion, to ensure effectiveness of the treatment, and to establish optimum treatment techniques and assessment of new sensitizers. The selection of the EPISCAN I-200 by the team at Christie Hospital is a testament to the device's quality, reliability and usefulness."

Skin cancer is one of the common forms of cancer in the UK. Official figures show that, in 2001, there were 70,038 cases of skin cancer registered in the UK. Of those, almost 63,000 were non-melanoma. In the USA, the American Cancer Society estimates that during 2005, 1 million new cases of basal cell or squamous cell carcinoma will be diagnosed.

Dr. Ernest Allan, Consultant Oncologist at the Christie Hospital said, "The EPISCAN I-200 will help us to accurately asses and treat non-melanoma skin cancers and Bowen's disease by providing high quality images of basal cell carcinoma initial thickness and regression as a result of photodynamic therapy (PDT) treatment. We have examined competing technologies and determined that the EPISCAN offers the most suitable imaging solution for our needs.

"The initial assessment and mapping of the regression of basal cell carcinoma (BCC) after PDT is an important aspect of our non-melanoma skin cancer program at the Christie Hospital. High-frequency pulsed ultrasound provides noninvasive information on skin and lesion thickness. This avoids repeated biopsies and ensures that the maximum tumor thickness is identified.

"The three fundamental elements of PDT are oxygen, a photosensitiser, and visible light. The photosensitiser may be applied topically or occasionally given systemically. It is selectively taken up by the tumor and is activated by the light at a wave length of 630 nm. It then interacts with molecular oxygen to produce an excited state-reactive singlet oxygen. This moity is highly cytotoxic and leads to the destruction of tumor cells.

"PDT is a developing technique which can produce total tumor resolution, while sparing normal tissue. It is therefore a minimally invasive procedure with subsequent rapid normal tissue healing and excellent cosmesis. It is highly effective in the eradication of Bowen's Disease and superficial basal cell carcinomas. Scientific research based on accurate tumor thickness measurement by the use of ultrasound imaging is enabling us to work towards PDT eradication of thicker tumors."

About Longport, Inc.

Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights, and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com.

About Christie Hospital

The Christie Hospital NHS Trust is an internationally recognized comprehensive cancer centre offering high quality diagnosis, treatment and care for the people of Greater Manchester and Cheshire in north west England. World class research from the laboratory bench to the patient clinic and education in all aspects of cancer is undertaken at the Christie. It is the largest single-site cancer treatment centre in Europe - covering a population of 3.2 million. It has been engaged in cancer treatment for over 100 years and counts among its milestones the first use of Roentgen X-rays in cancer treatment in 1901, radium therapy in 1905, the first clinical trial of a breast cancer drug in 1944, world's first clinical use of tamoxifen for breast cancer in 1970, the world's first use of cultured bone marrow for leukemia treatment in 1986, and the world's first single harvest blood stem-cell transplant in 1991.

Forward-looking Information and the Private Securities Litigation Reform Act of 1995

Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.